Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16195433 | 0.88 | EPHX2 (0.44) | EPHX2KDM4EALDH1A1LMNAHTR2A | |
| SCHEMBL16195436 | 0.88 | EPHX2 (0.44) | EPHX2KDM4EALDH1A1LMNAHTR2A | |
| SCHEMBL14968880 | 0.85 | CHEK1 (0.46) | EPHX2SUV39H2MAPTALDH1A1STS | |
| SCHEMBL14968881 | 0.85 | CHEK1 (0.46) | EPHX2SUV39H2MAPTALDH1A1STS | |
| SCHEMBL14965496 | 0.84 | EPHX2 (0.44) | EPHX2TGFBR1KDM4EPKMSUV39H2 | |
| SCHEMBL14965473 | 0.83 | EPHX2 (0.43) | EPHX2TGFBR1SUV39H2TP53MAPT | |
| SCHEMBL16206572 | 0.82 | HTR2A (0.43) | EPHX2MAPTALDH1A1LMNAHTR2A | |
| SCHEMBL2593352 | 0.82 | MAPT (0.49) | EPHX2SUV39H2MAPTALDH1A1LMNA | |
| SCHEMBL14965460 | 0.78 | EPHX2 (0.42) | EPHX2TP53MAPTALDH1A1CHEK1 | |
| SCHEMBL14968763 | 0.76 | EPHX2 (0.38) | EPHX2KDM4EMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2780331-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | Sentinel Oncology Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072502-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072502-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | PHKG1, PHKG2, PLK2 | EPHX2 1557/4885TGFBR1 2106/4885KDM4E 1234/4885 |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | PHKG1, PHKG2, PEAK1 | EPHX2 1594/4885TGFBR1 2211/4885KDM4E 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.